Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price target.
Read original at benzingaStocks · News reference
Reported Earlier, Telix FY2026 Revenue Guidance $950M-$970M Plus $40M Regeneron Payment, Total Expected Above $1B
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 21, 2026, 6:43 AM
- Checked
- Jul 21, 2026, 6:43 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Reported Earlier, Telix Pharmaceuticals Guides FY 2026 Revenue Of $950M-$970M, Total Income Above $1B, Reaffirms R&D Guidance Of $230M-$270M
Read original at benzingaReported Earlier, Telix Pharmaceuticals Reports H1 2026 Revenue Of $477M, Up 22% YoY, And Profit After Tax Of $38M Versus $2M Loss
Read original at benzingaTelix H1 2026 Results: Investor Webcast Notification
Telix Pharmaceuticals announced it will release its half-year financial results for June 30, 2026 on August 20, 2026, with an accompanying investor webcast and conference call. The company reported Q2 2026 revenue of US$247M with strong commercial momentum and pipeline progress across its radiopharmaceutical portfolio.
Read original at globenewswire-inc